AVIRAtea Pharmaceuticals, Inc.
What is the market doing?
No clear lean: rangebound and heavily shorted.
Rangebound, no clear trend. Oversold (RSI 16). Price is −18% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AVIR is trading
Atea Pharmaceuticals, Inc. is +23% over the past year while the S&P 500 is +16%: 7.2 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −18%
vs 200-day average · a clear downtrend
- RSI (14)
- 16
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 34%
Below its 52-week high
Details›
- Last close2026-10-23
- $4.04
- 1 monthS&P 500 −0.94%
- −22%
- 1 yearS&P 500 +16%
- +23%
- 5 yearsS&P 500 +86%
- −90%
- vs 50-day average$5.16
- −22%
- 52-week high
- $6.15
- 52-week low
- $2.96
- Annualised volatility
- 48%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-22
- $25K
| Year | Return |
|---|---|
| 2026 (year to date) | +13% |
| 2025 | +6.6% |
| 2024 | +9.8% |
| 2023 | −37% |
| 2022 | −46% |
| 2021 | −79% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +16% |
| Feb | 6 | 3 of 6 | −3.1% |
| Mar | 6 | 2 of 6 | −0.36% |
| Apr | 6 | 1 of 6 | −15% |
| May | 6 | 3 of 6 | +3.9% |
| Jun | 6 | 2 of 6 | +0.00% |
| Jul | 6 | 5 of 6 | +6.9% |
| Aug | 6 | 3 of 6 | +2.6% |
| Sep | 6 | 1 of 6 | −7.8% |
| Oct | 6 | 3 of 6 | −11% |
| Nov | 6 | 2 of 6 | −8.3% |
| Dec | 6 | 5 of 6 | +8.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.